Divis Laboratories
Divis Laboratories, a leading player in the pharmaceutical and biotechnology sectors, is headquartered in Hyderabad, India. Founded in 1990, the company has established itself as a prominent manufacturer of active pharmaceutical ingredients (APIs) and intermediates, catering to a global clientele. With a strong focus on research and development, Divis Laboratories has achieved significant milestones, including the successful launch of several high-quality products that meet stringent regulatory standards. The company’s core offerings include APIs for various therapeutic areas, particularly in anti-retroviral and anti-cancer medications, which are distinguished by their purity and efficacy. Divis Laboratories is recognised for its robust market position, consistently ranking among the top suppliers in the industry. Its commitment to innovation and sustainability further enhances its reputation as a trusted partner in the pharmaceutical landscape.
DitchCarbon Score
How does Divis Laboratories's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Divis Laboratories's score of 31 is higher than 90% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Divis Laboratories's reported carbon emissions
In 2023, Divis Laboratories, headquartered in India, reported significant carbon emissions, with Scope 1 emissions totalling approximately 380,676,000 kg CO2e and Scope 2 emissions at about 373,141,000 kg CO2e. This reflects a commitment to transparency in their environmental impact, as they have disclosed emissions data for both scopes. The company has set ambitious reduction targets, aiming to decrease the intensity of their greenhouse gas emissions (Scope 1 and Scope 2) by 25% by 2030. This initiative is part of their near-term strategy to enhance sustainability and reduce their carbon footprint. Additionally, Divis Laboratories has committed to achieving net-zero emissions across all scopes by 2050, aligning with global climate action goals. This long-term commitment underscores their dedication to addressing climate change and promoting sustainable practices within the pharmaceutical and biotechnology sector. Overall, Divis Laboratories is actively working towards reducing its carbon emissions while maintaining transparency and accountability in its environmental initiatives.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 380,676,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 373,141,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Divis Laboratories is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
